期刊文献+

糖皮质激素性骨质疏松的药物防治 被引量:1

原文传递
导出
摘要 糖皮质激素是临床常用药物之一,其引起的骨质疏松已经成为威胁公众健康的重要问题。目前已有多种治疗措施可有效地避免和延缓糖皮质激素性骨质疏松的发生。随着对其发病机制的深入研究,新的治疗措施不断涌现。本文简述了目前糖皮质激素性骨质疏松药物治疗方面的研究成果,包括常用药物如钙剂、维生素D、二膦酸盐、性激素等,新药物如甲状旁腺激、降钙素等及潜在性药物sclerostin的抗体、AMG162、calbindin-D28等。
出处 《国际泌尿系统杂志》 2007年第3期399-402,共4页 International Journal of Urology and Nephrology
  • 相关文献

参考文献24

  • 1Staa TP,Leufkens HG,Cooper C. The epidemiology of corticosteroid -induced osteoporosis:a metaanalysis. Osteoporos Int,2002,13:777 -787.
  • 2Albrecht W. Popp, Juerg Isenegger, Elizabeth M. Buergi, et al. Glucocorticosteroid -induced spinal osteoporosis: scientific update on pathophysiology and treatment. Eur Spine J,2006,15 : 1035 - 1049.
  • 3Compston J. US and UK guidelines for glucocorticoid - induced osteoporosis: similarities and differences. Curr. Rheumatol. Rep, 2004,6:66 -69.
  • 4Richy F, Ethgen O, Bruyere O, et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroidinduced osteoporosis: a meta -analysis of their e. ects on bone mineral density and fracture rate. Osteoporos Int ,2004,15:301 -310.
  • 5陈航,王梅.原发性肾小球疾病应用糖皮质激素患者骨密度情况及骨质疏松预防现状[J].中华肾脏病杂志,2005,21(11):695-696. 被引量:6
  • 6Ringe JD,Dorst A,Faber H,et al. Superiority of alfacalcidol over plain vitamin D in the treatment of glueocorticoid - induced osteoporosis. Rheumatol Int,2004,24:63-70.
  • 7Roux C, Oriente P, Laan R, et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid induced bone loss: Ciblos Study Group. J Clin Endocrinol Metab, 1998,83 : 1128 - 1133.
  • 8Boutsen Y, Jamart J, Esselinckx W,et al. Primary prevention of glucocorticoid -induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1 - year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res, 2001,16:104 -112.
  • 9Lems WF,Lodder MC,Lips P,et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low - dose prednisone : a randomized,double - blind. Osteoropos Int,2006,17:716 -723.
  • 10Wallach S, Cohen S, Reid DM,et al. E. ects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int,2000,67:277 -285.

二级参考文献4

  • 1Fujita T, Satomura A, Hidaka M, et al. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephritic patients receiving high - dose glucocorticoid and one-cycle etidronate therapy. Calcif Tissue Int, 2000, 66:195-199.
  • 2McKenzie R, Reynolds JC, O'Fallon A, et al. Decresed bone mineral during low dose glucocorticoid administration in a randomised-placebo controlled trial. J Rheumatol, 2000,27: 2222-2225.
  • 3Adachi J, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med, 1997, 337: 382-387.
  • 4Gulati S, Godbole M, Singh U, et al. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease. Am J Kidney Dis, 2003,41:1163-1169.

共引文献5

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部